

The logo for the European Bioanalysis Forum (EBF) is located in the top right corner. It consists of the letters 'EBF' in a white, sans-serif font. Below the letters is a white graphic element consisting of two curved lines that sweep upwards and to the right, resembling a stylized 'E' or a swoosh.

European  
Bioanalysis  
Forum

# Update on the EBF Topic-teams

Arjen Companjen,  
on behalf of the EBF IGM

EBF meeting 16 - 18 Nov 2011  
Barcelona

# Topic-teams

Stability of antibody reagents

Sense/non-sense of assessing NAb

Challenges of total versus free macromolecule quantification

Sample storage stability at very low temperatures

Design Of Experiment (DOE)

Selection of samples for ISR

# Topic-teams

Stability of antibody reagents

Sense/non-sense of assessing NAb

Challenges of total versus free macromolecule quantification

Sample storage stability at very low temperatures

Design Of Experiment (DOE)

Selection of samples for ISR

# Topic-team 18

## Stability of antibody reagents

*Goal:* To discuss how to assess the stability of antibody reagents in ligand binding assays (to be extended to other assay specific reagents)

*Expected outcome:* An EBF position paper on important steps during testing stability of assay specific reagents to be used in LBA

*Status:* Discussions are currently focussing on stability of antibody reagents (survey being put together)

# Topic-team 19

## Sense/non-sense of assessing NAb

*Goal:* To explore an alternative/additional way of monitoring effects of ADA responses

*Expected outcome:* An EBF position paper on the relevance of assessment of PK/PD profiles in ADA<sup>+</sup> and ADA<sup>-</sup> subjects

*Status:* A survey was performed which is now evaluated

# Topic-team 20

## Challenges of total versus free macromolecule quantification

*Goal:* To discuss the challenges of determining free and total drug/target in biological matrix

*Expected outcome:* Write a EBF position paper on the subject to create awareness with our stakeholders and provide recommendations on how to characterize the assay

*Status:* Survey on free/total drug-ligand assessment has been performed and evaluated and a breakout session during this symposium was organized